Table S1 from Anlotinib Plus Epirubicin Followed by Anlotinib Maintenance As First-line Treatment for Advanced Soft-tissue Sarcoma: an Open-label, Single-arm, Phase II Trial

Zhi-ming Wang,Rongyuan Zhuang,Xi Guo,Chen-lu Zhang,Yang You,Li-sha Chen,Wen-shuai Liu,Yong Zhang,Rongkui Luo,Yingyong Hou,Weiqi Lu,Yuhong Zhou

DOI: https://doi.org/10.1158/1078-0432.22488447.v1

2023-01-01

Abstract:Representativeness of Study Participants

What problem does this paper attempt to address?

Table S1 from Anlotinib Plus Epirubicin Followed by Anlotinib Maintenance As First-line Treatment for Advanced Soft-tissue Sarcoma: an Open-label, Single-arm, Phase II Trial

Zhi-ming Wang,Rongyuan Zhuang,Xi Guo,Chen-lu Zhang,Yang You,Li-sha Chen,Wen-shuai Liu,Yong Zhang,Rongkui Luo,Yingyong Hou,Weiqi Lu,Yuhong Zhou

DOI: https://doi.org/10.1158/1078-0432.22488447

2023-01-01

Abstract:Representativeness of Study Participants
Anlotinib Plus Epirubicin Followed by Anlotinib Maintenance As First-line Treatment for Advanced Soft-tissue Sarcoma: an Open-label, Single-arm, Phase II Trial

Zhi-ming Wang,Rong-yuan Zhuang,Xi Guo,Chen-lu Zhang,Yang You,Li-sha Chen,Wen-shuai Liu,Yong Zhang,Rong-kui Luo,Ying-yong Hou,Wei-qi Lu,Yu-hong Zhou

DOI: https://doi.org/10.1158/1078-0432.ccr-22-1903

IF: 13.801

2022-01-01

Clinical Cancer Research

Abstract:Abstract Purpose: The treatment outcome for locally advanced or metastatic soft-tissue sarcoma (STS) remains unsatisfactory. Anlotinib had demonstrated impressive activity in the subsequent-line treatment of STS. This study investigated the combination of anlotinib and epirubicin followed by anlotinib maintenance as first-line treatment for patients with advanced STS. Patients and Methods: This prospective, open-label, single-arm, phase II trial was conducted in Zhongshan Hospital, Fudan University. Eligible patients were ages 18 years or older and had previously untreated, pathologically confirmed, unresectable locally advanced or metastatic STS. All patients received up to six cycles of anlotinib plus epirubicin followed by anlotinib maintenance until disease progression, unacceptable toxicity, or death. The primary endpoint was the progression-free survival (PFS) rate at 6 months. The study was registered on chictr.org (identifier ChiCTR1900024928). Results: From June 2019 to August 2020, 30 patients were enrolled. By December 2021, the median PFS was 11.5 months [95% confidence interval (CI): 8.6–14.4 months], while the median overall survival was not reached (95% CI: NE–NE). The objective response rate was 13.33% and the disease control rate was 80.0%. The most common adverse events (AE) included anemia (43.3%), nausea/vomiting (40.0%), fatigue (36.7%), leukopenia (30.0%), and proteinuria (10.0%), which were mainly of grade 1 or 2. The most frequent grade 3 or 4 AEs were anemia (10.0%), febrile neutropenia (33.3%), hypothyroidism (3.3%), and leukopenia (3.3%). No treatment-related death occurred. Conclusions: The combination of anlotinib and epirubicin followed by anlotinib maintenance demonstrated promising efficacy with a favorable safety profile.
Anlotinib plus epirubicin followed by anlotinib maintenance as first-line treatment for advanced soft tissue sarcoma: an open-label, single-arm, phase 2 trial

Xi Guo,Yang You,Yong Zhang,Zhi-ming Wang,Rong-yuan Zhuang,Chen-lu Zhang,Li-sha Chen,Wen-shuai Liu,Rong-kui Luo,Ying-yong Hou,Wei-qi Lu,Yu-hong Zhou

DOI: https://doi.org/10.1158/1078-0432.ccr-22-1903

IF: 13.801

2022-10-15

Clinical Cancer Research

Abstract:Purpose: The treatment outcome for locally advanced or metastatic soft tissue sarcoma (STS) remains unsatisfactory. Anlotinib had demonstrated impressive activity in the subsequent-line treatment of STS. This study investigated the combination of anlotinib and epirubicin followed by anlotinib maintenance as first-line treatment for patients with advanced STS. Patients and methods: This prospective, open-label, single-arm, phase 2 trial was conducted in Zhongshan Hospital, Fudan university. Eligible patients were aged 18 years or older and had previously untreated, pathologically confirmed, unresectable locally advanced or metastatic STS. All patients received up to 6 cycles of anlotinib plus epirubicin followed by anlotinib maintenance until disease progression, unacceptable toxicity or death. The primary endpoint was the progression-free survival (PFS) rate at 6 months. The study was registered on chictr.org (identifier ChiCTR1900024928). Results: From June 2019 to August 2020, 30 patients were enrolled. By December 2021, the median PFS was 11.5 months (95% CI: 8.6-14.4 months), while the median overall survival (OS) was not reached (95% CI: NE-NE). The objective response rate (ORR) was 13.33% and the disease control rate (DCR) was 80.0%. The most common adverse events (AEs) included anemia (43.3%), nausea/vomiting (40.0%), fatigue (36.7%), leukopenia (30.0%) and proteinuria (10.0%), which were mainly of grade 1 or 2. The most frequent grade 3 or 4 AEs were anemia (10.0%), febrile neutropenia (33.3%), hypothyroidism (3.3%), and leukopenia (3.3%). No treatment-related death occurred. Conclusions: The combination of anlotinib and epirubicin followed by anlotinib maintenance demonstrated promising efficacy with a favorable safety profile.

oncology
Supplementary Data 1 from First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: an Open-Label, Single-Arm, Phase 2 Clinical Trial

Tao Li,Ying Dong,Yongzhong Wei,Shoufeng Wang,Yunxia Liu,Jia Chen,Wenhua Xiong,Nong Lin,Xin Huang,Meng Liu,Xiaobo Yan,Zhaoming Ye,Binghao Li

DOI: https://doi.org/10.1158/1078-0432.27142227

2024-01-01

Abstract:Supplementary File 1. Inclusion and exclusion criteria.Supplementary Table S1. Representativeness of trial patients.Supplementary Table S2. Summary of adverse events.
Phase II Study of Anlotinib for Treatment of Advanced Soft Tissues Sarcomas.

Yihebali Chi,Yongkun Sun,Jianqiang Cai,Yang Yao,Xiaonan Hong,Zhiwei Fang,Ping Sun,Guowen Wang,Qiong Wu,Guofan Qu,Shusen Wang,Jianmin Song,Jianchun Yu,Yongkui Lu,Xia Zhu,Xiaohui Niu,Zhiyong He

DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.11005

IF: 45.3

2016-01-01

Journal of Clinical Oncology

Abstract:11005 Background: No standard therapies are available in China for Soft tissues sarcomas (STS)patients who failed to chemotherapies. Anlotinib is a multi-target RTK inhibitor, with VEGFR1/2/3, FGFR1/2/3, PDGFRα/β, c-Kit, Ret ect. Recommended dose in phase I is 12 mg daily, 2 weeks on/1 week off. This single-arm, multi-center phase II study (NCT01878448) to assess efficacy and safety of Anlotinib for treatment of STS patients who failed to conventional therapies. Methods: Pathological types of advanced STS mainly include malignant fibrous histiocytoma (MFH), liposarcoma, leiomyosarcoma, synovial sarcoma (SS) and other sarcomas, but excluding RMS, chondrosarcoma, GIST etc. Patients with measurable indicators (RECIST1.1) were treated with Anlotinib. Efficacy was assessed every 6 weeks. The primary endpoint was disease PFR at week 12 (PFR12w ). Results: From April 2013, we recruited 166 patients in 15 centers in China, including 100 males and 66 females, average age is 44 (15-70). Pathological types included SS (n=47), leiomyosarcoma (n=26), fibrosarcoma (n=18), MFH (n=19), alveolar soft part sarcoma (ASPS, n=13), liposarcoma (n=13), others (n=30). As of May 2015, 154 patients were assessable for efficacy: PFR12w was 57.23%, mPFS was 5.63 months.22 patients achieved PR over time (19 pts confirmed, and ORR was 11.45%. See below table. 166 patients were assessable for safety. Common grade III/IV AEs include: hypertension(n=8), pneumothorax(n=5), thyroid hypofunction(n=2), proteinuria(n=1), hand-foot-skin reaction(n=1), diarrhea(n=1), triglyceride increase (n=2), hyperglycemia (n=1). 24 patients (14.5%) had dose adjustment during treatment, reducing to 10 mg daily, 2 weeks on/1 week off. Conclusions: Anlotinib is effective to many pathological types of soft tissue sarcoma, particularly to ASPS and SS. Overall PFR12w reached 57.23%. Meanwhile, Anlotinib is well tolerated, while pneumothorax needs to be noticed. A randomized, controlled clinical trial is ongoing. Yihebali Chi and Sun Yongkun contributed equally to this work. Clinical trial information: NCT01878448. Case (n) RR% PFR12w % Overall 166 11.45 57.23 SS 47 12.77 63.83 leiomyosarcoma 26 7.69 69.23 fibrosarcoma 18 11.11 61.11 MFH 19 5.26 47.37 liposarcoma 13 7.69 53.83 ASPS 13 46.15 76.92 others 30 3.33 33.33
A phase II study of anlotinib in the first-line treatment of locally advanced or metastatic soft-tissue sarcoma: Updated results.

Tao Li,Zhaoming Ye,Yongzhong Wei,Shoufeng Wang,Yunxia Liu,Jia Chen

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.e23559

IF: 45.3

2022-06-01

Journal of Clinical Oncology

Abstract:e23559 Background: Standard treatment for patients with unresectable locally advanced or metastatic soft-tissue sarcoma is chemotherapy based on anthracyclines, while the tolerance of chemotherapy is limited. Anlotinib had demonstrated promising efficacy and favorable tolerance in the first-line treatment of these patients in the previously report ( 2021 ASCO). We updated the latest long-term efficacy and safety data. Methods: This multicenter, open-label, single-arm, phase II clinical trial (NCT03792542) was done at 7 hospitals in China. Patients diagnosed with locally advanced or metastatic soft-tissue sarcoma who had evaluable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 were eligible for inclusion. Additional inclusion criteria were 1) 18-70 years old, 2) ECOG PS 0-2, 3) chemotherapy intolerance judged by investigators, 4) chemotherapy and anti-angiogenesis treatment naïve. All patients received 12mg anlotinib once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). Safety assessment was done in patients who received at least one dose of anlotinib. Results: 39 patients (24 males and 15 females) were enrolled between April 2019 to October 2021with a median follow-up 13.4 months (IQR 6.55-19.40), and the median age is 58 (range 23-69) years old. Pathological types included liposarcoma (n = 11), fibrosarcoma (n = 8), undifferentiated pleomorphic sarcoma (n = 5), leiomyosarcoma (n = 4), synovial sarcoma (n = 4), malignant peripheral nerve sheath tumor (n = 4), and others (n = 3). At the data cutoff date on December 27, 2021, the median PFS and median overall survival (OS) were 7.1 months [95%CI 5.42-8.77], 24.3 months [95%CI 14.9-33.7], respectively. The PFS at 6 months was 60.0%, and the OS at 12 months was 76.6%. 37 patients were eligible for the evaluation of tumor response.1 achieved confirmed partial response (PR) and the objective response rate (ORR) was 2.7% (1/37). 30 had stale disease (SD) and the disease control rate (DCR) was 83.8% (31/37). The incidence of adverse events of grade 3 was 33.3%, with a higher incidence of hypertension (12.8%), proteinuria (7.7%) and fatigue (5.1%). Conclusions: Anlotinib has shown encouraging anti-tumor activity and well tolerance in the first-line treatment of locally advanced or metastatic soft-tissue sarcoma who were not suitable for chemotherapy. Clinical trial information: NCT03792542.

oncology
A phase II study of epirubicin combined with anlotinib followed by anlotinib in the first-line treatment of advanced unresectablesoft tissue sarcoma.

Yuhong Zhou,Zhiming Wang,Rongyuan Zhuang,Xi Guo,Chenlu Zhang,Yang You,Lisha Chen,Wenshuai Liu,Yong Zhang,Weiqi Lu

DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.e23536

IF: 45.3

2021-01-01

Journal of Clinical Oncology

Abstract:e23536 Background: Anlotinib, a multi-target TKI,showed well efficiency and tolerance for the treatment of recurrent or metastatic soft tissue sarcoma (STS). Moreover, the synergistic activity of anlotinib plus epirubicin on the sarcoma PDX modelwas confirmed in our previous preclinical study. This phase II clinical study was designed to assess the efficacy and safety of epirubicin combined with anlotinib followed by anlotinib in the first-line treatment of advanced unresectable STS. Methods: This study is an open-label, prospective, single-arm phase II clinical study. Patients (pts) with locally advanced or metastatic soft tissue sarcomas confirmed by histopathology and not suitable for surgery were recruited, and treated with 6 cycles of anlotinib and epirubicin (epirubicin 90mg/m 2 CIV for 48 hours on day 1 and anlotinib 12 mg QD on day1-14, 21 days per cycle), followed by anlotinib alone unless the pts experienced progression or intolerance. Tumor imaging evaluations and echocardiography were performed every 2 cycles during combined therapy, and were performed every 3 cycles during the sequential anlotinib treatment. The primary end point was the progression-free rate at 12 weeks (PFR 12w ) and 6 months (PFR 6m ), secondary endpoints included ORR, PFS, safety, DCR and OS. Results: 33 eligible pts were enrolled from June 2019 to August 2020, and 3 pts dropped out without completing one cycle of treatment. Of 30efficacy-evaluable pts,10 were man, median age was 48 (range 18-74). The main subtypes included 10 leiomyosarcoma, 8 fibrosarcoma, 5 dedifferentiated liposarcoma, 4 synovial sarcoma, 2 undifferentiated pleomorphic sarcoma, and 1 epithelioid sarcoma. The average number of combined treatment cycle is 4.7 (range 2-6), 13 pts had entered into anlotinib maintenance treatment. The PFR 12w , PFR 6m , ORR, DCR were 70%,53.8%, 13.3%, and 80%,respectively. Median PFS was 11.5 months (95%CI: 5.0-NA), median OS has not been reached. As cut-off on Jan 20th 2020, 6 pts are still in treatment. The other pts discontinued trial due to disease progression (16/24), adverse events (AEs) (3/24), changes in treatment strategy because of tumor shrinkage (3/24), cytoreductive surgery (1/24), and opt-out (1/24). The main AEs were grade III-IV neutropenia (8/30, 26.7%), and 7 of them were febrile neutropenia (7/30, 23.3%). Until now, no cardiac-related AEswere observed. Conclusions: Advanced unresectable STS pts could benefit from epirubicin combined with anlotinib followed by anlotinibtreatment in first line. And it is generally well tolerated especially with no short-term cardiac toxicity. Clinical trial information: ChiCTR1900024928.
Anlotinib hydrochloride capsules for advanced soft tissue sarcoma: single-center data analysis of a stageⅡmulticenter clinical trial

Liu Jiayong,Fan Zhengfu,Li Shu,Xue Ruifeng,Gao Tian,Bai Chujie,Zhang Lu,Tan Zhichao,Fang Zhiwei

DOI: https://doi.org/10.3969/j.issn.1000-8179.2018.20.632

2018-01-01

Chinese Journal of Clinical Oncology

Abstract:Objective: To investigate the efficacy and safety of anlotinib hydrochloride capsules for the treatment of advanced soft tissue sarcoma based on the data from Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital&Institute. Methods: Patients were randomized allocated at 2:1 ratio for the anlotinib treatment and placebo group. The treatment group received 12 mg/day of anlotinib for 14 consecutive days in a 21-day cycle. The primary end-point was progression-free survival (PFS), and the secondary end-points were disease control rate (DCR), overall survival (OS), and adverse event rate. Results: A total of 46 patients were enrolled in this study; 7 of them were excluded from per protocol set (PPS). Among the remaining 39 patients, 28 were included in the anlotinib group and 11 in the placebo group. In the anlotinib group, 4 patients had partial remission and 13 had stable disease (SD), whereas in the placebo group, 3 patients had SD. The difference in DCR between the 2 groups was statistically significant (60.7% vs . 27.3%, P=0.082). The DCR of the advanced soft tissue sarcoma in the anlotinib group was 78.6% (11/14). The median PFS in the anlotinib group was 12.4 (95% confidence interval [CI]: 7.6 to 17.2) months, which was significantly longer than 4 months in the placebo group (95% CI: 1.7 to 6.3 months, P=0.043); however, the difference in OS between the 2 groups was not significant (19.4 vs . 17.6 months, P=0.961). Regarding the safety, 2 patients had severe adverse events (7.14%) possibly related with treatment in the anlotinib group; one of them had pneumothorax. The other adverse events were grade 1 to 2. Conclusions: Soft tissue sarcoma is highly responsive to anlotinib, with prolonged PFS. Anlotinib is well tolerated and can be used as a treatment option for advanced soft tissue sarcoma.
Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial.

Zengjun Liu,Mengyao Liu,Jing Xu,Wenyu Hu,Dongyuan Zhu,Rongjie Tao,Ni Xu,Hui Zhang,Minghuan Li

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.11553

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:11553 Background: Anthracycline plus ifosfamide is the standard first line treatment regime for advanced soft tissue sarcoma (STS). Anlotinib, a multikinase angiogenesis inhibitor, has evolved as a standard second line treatment option in Chinese advanced STS patients. This study was performed to evaluate the efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in the first line treatment of patients with advanced STS. Methods: This prospective, open-label, single-arm, phase 2 trial was conducted in Shandong Cancer Hospital and Institute (ChiCTR2100054711). The key inclusion criteria included: (a) age was 18-70 years; (b) ECOG performance state of 0-1; (c) histologically confirmed high-grade STS; (d) unresectable or metastatic STS; (e) previously untreated, and sensitive to chemotherapy; (f) having measurable lesions according to RECIST 1.1. All patients received up to 6 cycles of anlotinib (12 mg QD on day1-14, 21 days per cycle) combined with anthracycline (epirubicin 40mg/m 2 /d on day 1-2, 21 days per cycle; or liposomal doxorubicin 30mg/m 2 /d on day 1, 21 days per cycle) and ifosfamide (2g/m 2 /d on day 1-3, 21 days per cycle) followed by anlotinib maintenance until disease progression, unacceptable toxicity or death. Pegylated recombinant human granulocyte colony-stimulating factor was administered following chemotherapy. The primary endpoint was objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), and adverse effect (AE). Results: From December 2021 to December 2022, 31 patients (median [range] age, 53 [18-69] years; 20 [64.5%] male) were enrolled. 29 were evaluable for objective response, and the ORR and DCR were 31.03% (95%CI, 17.28-49.23%) and 82.76% (95%CI, 65.45-92.4%), respectively. With a median follow-up duration of 6.3 months (range, 0.8–14.0), the median PFS for all 31 patients was 6.9 months (95% CI, 2.62-11.17). The median OS was not reached. Treatment-related AEs of any grade occurred in all patients. The most common AEs included nausea/vomiting (88.46%), anemia (23.08%), leukopenia (19.23%), venous thrombosis (15.38%), hand-foot syndrome (11.54%) and elevated alanine aminotransferase or aspartate aminotransferase (11.54%). The most frequent ≥ grade 3 AEs were leukopenia (11.54%) and thrombocytopenia (7.69%). 2 serious AEs (1 left heart failure and 1 intestinal obstruction) were recorded. No treatment-related death occurred. Conclusions: This study suggested that anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance demonstrated encouraging efficacy with a manageable safety profile in the first line treatment of patients with advanced STS. Clinical trial information: ChiCTR2100054711 .

oncology
First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: an Open-Label, Single-Arm, Phase 2 Clinical Trial.

Tao Li,Ying Dong,Yongzhong Wei,Shoufeng Wang,Yunxia Liu,Jia Chen,Wenhua Xiong,Nong Lin,Xin Huang,Meng Liu,Xiaobo Yan,Zhaoming Ye,Binghao Li

DOI: https://doi.org/10.1158/1078-0432.ccr-23-3983

IF: 13.801

2024-01-01

Clinical Cancer Research

Abstract:Purpose: Standard treatment for patients with unresectable locally advanced or metastatic soft-tissue sarcoma (LA/M STS) is chemotherapy based on anthracyclines, but patient tolerance of chemotherapy is limited. The present trial (NCT03792542) investigated the use of anlotinib as first-line treatment for patients with advanced STS, in particular liposarcoma.Patients and Methods: Eligible patients were previously untreated, pathologically confirmed, unresectable LA/M STS cases. Anlotinib was given orally at a dose of 12 mg once daily from days 1 to 14 every 3 weeks until disease progression or intolerable adverse events (AE) occurred. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate, and disease control rate (DCR). The safety profile was also evaluated.Results: Forty patients were enrolled from April 2019 to June 2022 and are included in the intention-to-treat analysis. The median PFS was 6.83 months [95% confidence interval (CI), 4.17-8.71] and the median OS 27.40 months (95% CI, 16.43-not evaluable); 1 patient reached partial response and 26 attained stable disease, with a DCR of 67.5% (27/40). Median PFS and OS times for liposarcoma patients were 8.71 and 16.23 months, respectively. Ten (25.0%) patients had treatment-related AEs >= grade 3, with in particular a higher incidence of hypertension (15.0%) and proteinuria (7.5%).Conclusions: The findings suggest a potential benefit in using front-line anlotinib to treat patients with STS, who are not eligible for cytotoxic chemotherapy. Of note, the clinical outcomes for the liposarcoma subgroup of patients were encouraging. See related commentary by Napolitano et al., p. 4257Conclusions: The findings suggest a potential benefit in using front-line anlotinib to treat patients with STS, who are not eligible for cytotoxic chemotherapy. Of note, the clinical outcomes for the liposarcoma subgroup of patients were encouraging. See related commentary by Napolitano et al., p. 4257
Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006) a multicentre, open-label, single-arm, phase 2 trial

Bushu Xu,Qiuzhong Pan,Hua Pan,Haomiao Li,Xianan Li,Jing Chen,Danmei Pang,Baoqing Zhang,Desheng Weng,Ruiqing Peng,Meiyu Fang,Xing Zhang

DOI: https://doi.org/10.1016/j.eclinm.2023.102240

IF: 15.1

2023-01-01

EClinicalMedicine

Abstract:Background No standard maintenance treatment has been obtained to prolong the response duration of soft tissue sarcoma (STS) after first-line chemotherapy. In this study, we aimed to evaluate the efficacy and safety of anlotinib as a maintenance treatment after chemotherapy in STS.Methods In this multicentre, open-label, single-arm phase 2 trial, patients with advanced STS who achieved partial response or stable disease after first-line anthracycline-based chemotherapy were enrolled between April 2019 and January 2022. All patients received anlotinib as a maintenance treatment. The primary endpoint was progression-free survival (PFS) of anlotinib maintenance treatment. Other endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety. This study is registered with ClinicalTrials.gov, NCT03890068.Findings At the data cut-off date (August 8, 2022), 49 patients were enrolled, including 17 with liposarcoma (35%) and 15 with leiomyosarcoma (31%). After a median follow-up of 17.1 months (IQR 9.0-27.2), the median PFS from the beginning of maintenance treatment was 9.1 months (95% CI 5.7-12.5), and the median OS was not reached, and the 1-year OS rate for anlotinib maintenance treatment was 98.0%. The best ORR and DCR were 16% (8/49, 95% CI 7-30) and 94% (46/49, 95% CI 83-99), respectively. Most of the treatment-related adverse events were grade 1-2. Of the grade 3-4 adverse events, the most common were hypertension (10%) and hand-foot syndrome reaction (6%).Interpretation Postchemotherapy maintenance treatment with anlotinib exhibits promising efficacy and tolerable toxicity in patients with advanced STS.Copyright (c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

Yihebali Chi,Zhiwei Fang,Xiaonan Hong,Yang Yao,Ping Sun,Guowen Wang,Feng Du,Yongkun Sun,Qiong Wu,Guofan Qu,Shusen Wang,Jianmin Song,Jianchun Yu,Yongkui Lu,Xia Zhu,Xiaohui Niu,Zhiyong He,Jinwan Wang,Hao Yu,Jianqiang Cai

DOI: https://doi.org/10.1158/1078-0432.CCR-17-3766

2018-11-01

Abstract:Purpose: The prognosis for patients with refractory soft-tissue sarcoma (STS) is dismal. Anlotinib has previously shown antitumor activity on STS in preclinical and phase I studies.Patients and Methods: Patients 18 years and older, progressing after anthracycline-based chemotherapy, naïve from angiogenesis inhibitors, with at least one measurable lesion according to RECIST 1.1, were enrolled. The main subtypes eligible were undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), leiomyosarcoma (LMS), synovial sarcoma (SS), fibrosarcoma (FS), alveolar soft-part sarcoma (ASPS), and clear cell sarcoma (CCS). Participants were treated with anlotinib. The primary endpoint was progression-free rate at 12 weeks (PFR12 weeks).Results: A total of 166 patients were included in the final analysis. Overall, the PFR12 weeks was 68%, and objective response rate was 13% (95% confidence interval, 7.6%-18%). The median progression-free survival (PFS) and overall survival (OS) were 5.6 and 12 months, respectively. The PFR12 weeks, median PFS and OS were: 58%, 4.1 and 11 months for UPS (n = 19); 63%, 5.6 and 13 months for LPS (n = 13); 75%, 11 and 15 months for LMS (n = 26); 75%, 7.7 and 12 months for SS (n = 47); 81%, 5.6 and 12 months for FS (n = 18); 77%, 21 and not reached for ASPS (n = 13); 54%, 11 and 16 months for CCS (n = 7); and 44%, 2.8 and 8.8 months for other sarcoma (n = 23), respectively. The most common clinically significant grade 3 or higher adverse events were hypertension (4.8%), triglyceride elevation (3.6%), and pneumothorax (2.4%). No treatment-related death occurred.Conclusions: Anlotinib showed antitumor activity in several STS entities. The toxicity was manageable. Clin Cancer Res; 24(21); 5233-8. ©2018 AACR.
First Line Anlotinib Plus Liposomal Doxorubicin for Locally Advanced or Metastatic Soft Tissue Sarcoma: A Prospective, Single-Arm Trial

Xin Sun,Ranxin Zhang,Jie Xu,Lu Xie,Wei Guo

DOI: https://doi.org/10.4103/1995-7645.348155

2022-01-01

Asian Pacific Journal of Tropical Medicine

Abstract:Objective: To examine the efficacy and safety of anlotinib as first-line therapy to treat locally advanced or metastatic soft-tissue sarcoma.Methods: This is a single-arm trial. Treatment-na?ve patients (≥14 years) with locally advanced or metastatic soft tissue sarcoma were eligible. Each treatment cycle lasted for 3 weeks, and included liposomal doxorubicin (40-50 mg/m2) on day 1 and anlotinib (12 mg) on days 8-21. Starting from the 9th cycle, treatment consisted of only anlotinib. Treatment continued until disease progression or intolerable toxicities. The primary efficacy end point was progression-free survival (PFS). Results: Eight patients were enrolled between July 25, 2019 and January 8, 2020. The median number of treatment cycles was 5.5. Within 5.9 months median follow-up, PFS events occurred in 4 (4/8, 50％) patients. The median PFS was 11.3 months and the 6-month PFS rate was 56％. No patients attained complete response and 2 patients (fibrosarcoma, 1 patient and undifferentiated pleomorphic sarcoma, 1 patient) achieved partial response. Three patients (fibrosarcoma, 2 patients and synovial sarcoma, 1 patient) had stable disease. The objective response rate was 25％ (2/8) for the study population, and the disease control rate was 75％ (6/8). No new safety concerns emerged. Conclusions: Anlotinib plus liposomal doxorubicin demonstrated antitumor activities in previously untreated locally advanced or metastatic soft tissue sarcomas. Due to the small sample size, further investigations with a larger population should be undertaken to confirm the study findings.
A retrospective study of advanced progressive sarcoma treated by Anlotinib

Zuo-yao LONG,Ya-jie LU,Ming-hui LI,Guo-jing CHEN,Feng-wei WANG,Dong LIU,Hai HUANG,Hong-mei ZHANG,Zhen WANG

DOI: https://doi.org/10.3969/j.issn.2095-252X.2019.01.002

2019-01-01

Abstract:Objective To evaluate the efficacy of advanced progressive sarcoma treated by Anlotinib. Methods From June to November 2018, all advanced progressive sarcoma patients in our hospital were included. After evaluation of status, patients received Anlotinib 12 mg once daily, 2-week on/1-week off, in a 3-week cycle. Patients would have surgery first if they had surgical indications. Outcomes were assessed by tumor volume and imagelogy diversity. Toxicity was recorded using CTCAE version 4.03. Results Seventeen patients were enrolled. Ten of them were male, and the others were female, with a mean age of (41.7 ± 22.4) years. Pathological findings: 4 osteosarcoma, 3 chondrosarcoma, 3 undifferentiated polymorphous sarcoma, 2 epithelioid sarcoma, 2 leiomyosarcoma, 1 alveolar soft part sarcoma, 1 intraabdominal desmoplastic small round cell tumor, 1 fibrosarcoma. 2 patients had PR (11.76％), 11 patients had SD (64.70％), 4 patients had PD (23.54％). The ORR was 11.76％, and DCR was 76.46％. The most common adverse events were anorexia (35.29％), fatigue (23.53％), hypertension (11.76％). Conclusions Anlotinib shows antitumor activity in advanced progressive sarcoma entities with a manageable tolerability, which could be a new treatment approach.
P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Baohui Han,Kai Li,Yizhuo Zhao,Qiming Wang,Li Zhang,Jianhua Shi,Zhehai Wang,Jianxing He,Yuankai Shi,Yin Cheng,Weiqiang Chen,Xiuwen Wang,Yi Luo,Kejun Nan,Faguang Jin,Jian Dong,Baolan Li,Jianying Zhou,Yinlan Chen,Donglin Wang,Xin Zhou,Yan Yu,Liming Chen,Anwen Liu,Jianjin Huang,Cheng Huang,Bangwei Cao,Jun Chen,Rui Ma,Zhuang Yu,Cuimin Ding,Hongbing Wang

DOI: https://doi.org/10.1016/j.jtho.2016.11.1210

IF: 20.121

2017-01-01

Journal of Thoracic Oncology

Abstract:Anlotinib hydrochloride, a novel multi-targeted tyrosine kinase inhibitor (TKI) was found to exhibit excellent inhibitory efficiency on a variety of receptor tyrosine kinases (RTK) involved in tumor progression, especially the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and stem cell-factor receptor (c-Kit). This ongoing trial aimed at evaluating the efficacy and safety of anlotinib hydrochloride comparing with placebo in advanced NSCLC patients who had received at least two previous chemotherapy and EGFR/ALK targeted therapy regimens. This Phase III, randomized, double-blind, placebo-controlled study (NCT 02388919) is ongoing in 31 centers in China under the supervision of Independent Data Monitoring Committee (IDMC). Pathological stage IIIB/IV adult advanced NSCLC patients (Pts) who had failed with at least two previous chemotherapy and EGFR/ALK targeted therapy regimens were eligible. The status of EGFR and ALK genes should be clear in all enrolled pts. Pts with sensitive EGFR or ALK mutations must had received and appeared intolerance to pervious targeted therapies. Pts were randomized (2:1) to receive Anlotinib hydrochloride or placebo once daily (12 mg) from day 1 to 14 of a 21-day cycle until progression. Dose reduction to 8 or 10 mg/day could be applied when grade 3 or 4 treatment-related toxicities were observed. The minimal sample size was estimated to 450 patients. The primary endpoint is overall survival (OS) and second endpoints are progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR) and quality of life (QoL). Quality of life was assessed via EORTC QLQ-C30, safety is determined using standard NCI-CTCAE v4.02, and responses are evaluated according to RECIST v1.1. This study started in February 2015, up to early July 2016, a total of 420 pts have been enrolled (93.3 % of 450 pts). Among enrolled pts, about 80 % were diagnosed as adenocarcinoma, EGFR mutation or ALK rearrangement was found in 1/3 of the pts. The overall analyzes will start after 300 OS events. Anti-angiogenesis is the main mechanism of Anlotinib hydrochloride for preventing the tumor progression. Results of randomized, placebo-controlled Phase II trial (NCT01924195) has been reported in WCLC 2015, however, advantages in PFS (4.8 vs. 1.2 months) and OS (9.3 vs. 6.3 months) were observed in Anlotinib arm from the renewed data. Based on these exciting data, we are looking forward for the results of the Phase III trial.
Supplementary Table S5 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: an Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001

Yan Zhou,Qingcheng Yang,Yang Dong,Tong Ji,Bing Zhang,Cheng Yang,Shuier Zheng,Lina Tang,Chenliang Zhou,Guowei Qian,Yujing Huang,Wenxi Yu,Hongtao Li,Yonggang Wang,Aina He,Zan Shen,Qiyuan Bao,Yingqi Hua,Hongyu Bai,Jiayi Zhao,Xiaoyi Li,Xiangrong Dai,Jianjun Zhang,Haiyan Hu,Yang Yao

DOI: https://doi.org/10.1158/1078-0432.22489763

2023-01-01

Abstract:Representativeness of study participants
Efficacy and Safety of Anlotinib in Advanced Soft Tissue Sarcoma: Results from One of Multi-Centers in a Phase IIB Trial (ALTER0203).

Lina Tang,Yonggang Wang,Jianjun Zhang,Wenxi Yu,Yujing Huang,Yang Yao

DOI: https://doi.org/10.1200/jco.2019.37.15_suppl.e22518

IF: 45.3

2019-01-01

Journal of Clinical Oncology

Abstract:e22518 Background: There is no standard therapy for soft tissue sarcoma (STS) patients progressing after first-line chemotherapy. Anlotinib significantly prolonged PFS in advanced STS patients in the earlier results of ALTER0203. In view of regional differences, we further analysis results from Affiliated Sixth People’s Hospital, Shanghai Jiaotong University, one center in this IIB trial. Methods: Patients aged from 18 to 70 with advanced STS, progressing after anthracycline-based chemotherapy (not adapted to alveolar soft part sarcoma (ASPS) and clear cell sarcoma (CSC)), angiogenesis inhibitor naive, at least one measurable lesion according to RECIST 1.1, were eligible. Patients were randomised in a 2:1 ratio to receive anlotinib (12 mg per day 2 weeks on and 1 week off) or placebo. Primary endpoint was progression free survival (PFS). Secondary endpoints were overall response rate (ORR), disease control rate (DCR). Results: This center of ALTER0203 enrolled 48 eligible patients who received either anlotinib (n = 32) or placebo (n = 16). Leiomyosarcoma (LMS) (13/48), ASPS (12/48), synovial sarcoma (SS) (11/48) were major subtypes. The median PFS was 1.57 months (95% CI: 1.19-1.95) for placebo versus 6.27 months (95% CI: 1.89-10.65) for anlotinib ( P= 0.009). ORR was 0% (0/16) for placebo versus 18.75% (6/32) for anlotinib ( P= 0.16); DCR was 18.75% (3/16) for placebo versus 56.25% (18/32) for anlotinib ( P= 0.02). The most common adverse events (AEs) were hypertension, elevated TSH, hypertriglyceridaemia (HTG). The most common Grade ≥3 AEs were menstrual disorder, hypertension, gamma glutamyl transferase (GGT) elevation and lipase elevation. Conclusions: The efficacy and safety of anlotinib is further confirmed in advanced STS patients regarding regional differences. Clinical trial information: NCT02449343. [Table: see text]
Anlotinib for Metastasis Soft Tissue Sarcoma: A Randomized, Double-Blind, Placebo-Controlled and Multi-Centered Clinical Trial.

Yihebali Chi,Yang Yao,Shusen Wang,Gang Huang,Qiqing Cai,Guanning Shang,Guowen Wang,Guofan Qu,Qiong Wu,Yu Jiang,Jianmin Song,Jing Chen,Xia Zhu,Zhengdong Cai,Chunmei Bai,Yongkui Lu,Zhihua Yu,Jingnan Shen,Jianqiang Cai

DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.11503

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:11503 Background: No standard therapy is available in China for soft tissue sarcoma (STS) patients progressed after first-line chemotherapy. Anlotinib has shown single-agent activity in a phase II study presented orally at 2016 ASCO. This study aimed at confirming anlotinib’s efficacy and safety in advanced STS patients after failure of standard chemotherapy. Methods: Patients aged 18 years and older with angiogenesis inhibitor naive, histologically proven advanced STS, intolerance or failure to anthracycline-based chemotherapy, at least one measurable lesion according to RECIST 1.1, were eligible. Those patients were randomly assigned (2:1) to receive anlotinib (12 mg per day 2 weeks on and 1 week off) or placebo. The pathologic subtypes enrolled were: synovial sarcoma (SS), alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS) and others. Different pathologic subtypes were also randomly assigned (2:1) to each arm. The primary endpoint was progression-free survival (PFS). This trial was registered with ClinicalTrials.gov, number NCT02449343. Results: 233 patients were randomly assigned to either anlotinib (n = 158) or placebo (n = 75) and included in the final analysis. The median PFS was 6.27 months (95% CI: 4.30-8.40) for anlotinib compared with 1.47 months (95% CI: 1.43-1.57) for placebo (HR=0.33, p < 0.0001); objective response rate was 10.13% versus 1.33% (p = 0.0145); disease control rate was 55.7% versus 22.67% (p < 0.0001). For SS (n = 57), the median PFS was 5.73 months versus 1.43 months (HR = 0.2, p < 0.0001). For ASPS (n = 56), the median PFS was 18.23 months versus 3 months (HR = 0.14, p < 0.0001). For LMS (n = 41), the median PFS was 5.83 months versus 1.43 months (HR = 0.19, p < 0.0001). The most common grade 3 or higher adverse events were hypertension (18.99% with anlotinib vs 0 with placebo, p = 0.00), gamma glutamyl transferase elevation (4.43% vs 1.33%, p = 0.44), triglyceride increase (4.43% vs 0, p = 0.10), low density lipoprotein elevation (3.16% vs 2.67%, p = 1.00), hyponatremia (3.16% vs 1.33%, p = 0.67) and neutrophil count reduction (3.16% vs 0, p = 0.18). Conclusions: Anlotinib is a new treatment option for patients with advanced STS after failure of standard chemotherapy. Clinical trial information: NCT02449343.
Efficacy and Safety of Anlotinib Plus TQB2450 in Patients with Advanced Soft Tissue Sarcoma: A Multicenter, Single Armed, Phase 1b Trial.

Jiayong Liu,Zhengfu Fan,Wei Guo,Tian Gao,Shu Li,Jie Xu,Chujie Bai,Ruifeng Xue,Lu Zhang,Lu Xie,Zhichao Tan

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.11547

IF: 45.3

2021-01-01

Journal of Clinical Oncology

Abstract:11547 Background: Anlotinib, a multitargeted tyrosine kinase inhibitor, had been prove to be effective for the treatment of advanced or metastatic soft tissue sarcoma(STS) faild anthracycline chemotherapy. With the lack of prospective data of combination of PDL-1 inhibitor and antiangiogenic agent, we designed a phase 1b study to investigated the efficacy and safety of anlotinib plus TQB2450 in patients with STS. Methods: Eligible patients (age 18-70, ECOG 0-1, with histopathologically confirmed advanced STS, at least one measurable lesion according to RECIST 1.1, and previously received front-line anthracycline chemotherapy) were included and received anlotinib (12mg qd, D1-14, 21d/cycle) plus TQB2450 (1200 mg, IV, D1, 21d/cycle) until disease progression or intolerable toxicities.The primary endpoint was objective response rate (ORR), secondary endpoints included safety, overall survival (OS), progression-free survival (PFS), disease control rate (DCR). Results: From January 2019 to January 2021, 30 pts were enrolled1, 12 alveolar soft part sarcoma and 18 others (7 synovial sarcoma, 4 leiomyosarcoma, 5 undifferentiated pleomorphic sarcoma, 1 fibrosarcoma and 1 epithelioid sarcoma). ORR by RECIST was 36.7%, DCR was 83.3%, 11/30 pts had PR, 14/30 (46.7%) had SD, 5/30 (16.7%) PD. Median PFS was 9.6 m in all pts and 4.9m. in non-ASPS, respectively. Median OS in non-ASPS was 10.27m, while mOS in all pts and both mPFS and mOS in ASPS had not been reached. Notably, to ASPS pts, ORR was 75%, and DCR was 100%. The most common 1-2 grade treatment-related adverse reaction (TRAE) was hypothyroidism (19/30,63.3%)，hypercholesterolemia (16/30, 53.3%) and hypertriglyceridemia (16/30, 53.3%), the most common ≥3 grade TRAEs were hypertriglyceridemia (3/30, 10%). 6 SAE (20%) occurred, including 2 pneumothorax, 1 Immune associated hapatic injury, 1 hypotension, 1 Immune myocarditis and 1 diabetic ketoacidosis. Conclusions: The combination of anlotinib and TQB2450 showed promising activity in second-line treatment of advanced STS, especially in ASPS, with well tolerance and acceptable toxicity.
The Efficacy and Safety of Anlotinib Combined with Chemotherapy in Treatment of Advanced Soft Tissue Sarcoma

Ying Ni,Yabing Dong,Aijun Jiang,Qun Zhang,Zhantong Wang,Hui Liang,Wei Zhang

DOI: https://doi.org/10.1007/s12672-024-01492-1

2024-01-01

Discover Oncology

Abstract:To evaluate the efficacy and safety of anlotinib combined with chemotherapy in the treatment of advanced soft tissue sarcoma (STS). A total of 14 patients with advanced STS consisting of 4 liposarcoma, 3 undifferentiated polymorphous sarcoma, 2 synovial sarcoma, 1 Extraosseous ewing sarcoma, 1 spindle cell sarcoma, 1 Sarcomatoid malignant mesothelioma, 1 hemangiosarcoma, and 1 fibrosarcoma, were treated with anlotinib plus chemotherapy. The anlotinib was combined with chemotherapy as the first-line treatment in 13 patients, and as second-line treatment in 1 patient. Chemotherapy regimens were based on anthracyclines and ifosfamide, and other drugs included paclitaxel, and so on. Efficacy and safety were evaluated every 2 treatment cycles. According to the stage of AJCC, 9 patients were stage III and 5 patients were stage IV. The average cycle of treatment is 3.86. Among the 14 patients, 2 cases had received surgical treatment after neoadjuvant chemothrapy, 5 cases had partial response (PR), 7 cases had stable disease (SD), and 2 cases had progressive disease (PD). The overall response rate (ORR) was 35.7

Table S1 from Anlotinib Plus Epirubicin Followed by Anlotinib Maintenance As First-line Treatment for Advanced Soft-tissue Sarcoma: an Open-label, Single-arm, Phase II Trial

Table S1 from Anlotinib Plus Epirubicin Followed by Anlotinib Maintenance As First-line Treatment for Advanced Soft-tissue Sarcoma: an Open-label, Single-arm, Phase II Trial

Anlotinib Plus Epirubicin Followed by Anlotinib Maintenance As First-line Treatment for Advanced Soft-tissue Sarcoma: an Open-label, Single-arm, Phase II Trial

Anlotinib plus epirubicin followed by anlotinib maintenance as first-line treatment for advanced soft tissue sarcoma: an open-label, single-arm, phase 2 trial

Supplementary Data 1 from First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: an Open-Label, Single-Arm, Phase 2 Clinical Trial

Phase II Study of Anlotinib for Treatment of Advanced Soft Tissues Sarcomas.

A phase II study of anlotinib in the first-line treatment of locally advanced or metastatic soft-tissue sarcoma: Updated results.

A phase II study of epirubicin combined with anlotinib followed by anlotinib in the first-line treatment of advanced unresectablesoft tissue sarcoma.

Anlotinib hydrochloride capsules for advanced soft tissue sarcoma: single-center data analysis of a stageⅡmulticenter clinical trial

Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial.

First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: an Open-Label, Single-Arm, Phase 2 Clinical Trial.

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006) a multicentre, open-label, single-arm, phase 2 trial

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

First Line Anlotinib Plus Liposomal Doxorubicin for Locally Advanced or Metastatic Soft Tissue Sarcoma: A Prospective, Single-Arm Trial

A retrospective study of advanced progressive sarcoma treated by Anlotinib

P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Supplementary Table S5 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: an Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001

Efficacy and Safety of Anlotinib in Advanced Soft Tissue Sarcoma: Results from One of Multi-Centers in a Phase IIB Trial (ALTER0203).

Anlotinib for Metastasis Soft Tissue Sarcoma: A Randomized, Double-Blind, Placebo-Controlled and Multi-Centered Clinical Trial.

Efficacy and Safety of Anlotinib Plus TQB2450 in Patients with Advanced Soft Tissue Sarcoma: A Multicenter, Single Armed, Phase 1b Trial.

The Efficacy and Safety of Anlotinib Combined with Chemotherapy in Treatment of Advanced Soft Tissue Sarcoma